recombinant technology


Also found in: Dictionary, Thesaurus, Medical.

recombinant technology

[ri¦käm·bə·nənt tek′näl·ə·jē]
(genetics)
In genetic engineering, laboratory techniques used to join deoxyribonucleic acid (DNA) from different sources to produce novel DNA. Also known as gene splicing.
In genetic engineering, laboratory techniques used to join ribonucleic acid (RNA) from different sources to produce novel RNA.
References in periodicals archive ?
Department of Health and Human Services (HHS), awarded a contract to VaxInnate worth up to $196 million over five years to fund the development of seasonal and pandemic flu vaccines using recombinant technology.
VIII produced second-generation or more advanced technology in the fifth recombinant technology.
Octapharma Biopharmaceuticals GmbH is a subsidiary of Octapharma AG, one of the world's largest providers of human therapeutic proteins and one of the first companies using recombinant technology from human cells.
Contract notice: Produced by recombinant technology for the treatment of a sale and purchase agreement with congenital haemophilia 1st generation viii.
These new genes could potentially be utilized in our dual recombinant technology which will incorporate different angiogenic genes into unique combinations that may be used to optimize the treatment of particular cardiovascular diseases and patient populations.
Contract notice: Produced by recombinant technology, for the sale and purchase agreement for the treatment of congenital haemophilia 1st generation viii.
Manon Cox, Protein Sciences' vice president, corporate development, commented, "We now have a broad relationship with Pasteur Merieux Connaught with four agreements that encompass three different approaches to bringing recombinant technology to influenza vaccines and an umbrella agreement that simplifies the process of initiating projects to develop new subunit vaccines for other diseases.
com/research/k9tk5w/biosimilars_in_eme) has announced the addition of the "Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production" report to their offering.
Part 1 A third-generation VIII produced by recombinant technology.
New market study "Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production" developed by GBI Research provides true insights into the biosimilars market in emerging economies, with regional market forecasts for biosimilars in India and China, and analysis of the key drivers & restraints affecting the sector.
Eposis (EPO), a haematopoietic agent produced by genetic recombinant technology, is effective in treating the anemia of patients with chronic renal failure and has been exported to Turkey, Vietnam, Thailand, Indonesia, Sri Lanka, Pakistan, Syria, etc.

Full browser ?